Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Key Decisionmaking Factors in Resectable Non–Small Cell Lung Cancer

April 28th 2023

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

CTLA-4 Targeted Regimens in Advanced NSCLC

April 26th 2023

Solange Peters, MD, PhD, detail the subgroups of patients with advanced NSCLC and how treatment varies.

Dr Stewart on the Multiomic Landscape of Squamous Cell Lung Cancer

April 26th 2023

Paul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.

VT3989 Shows Activity, Tolerability in Mesothelioma and Other NF2-Mutated Solid Tumors

April 26th 2023

VT3989, a first-in-class YAP/TEAD inhibitor, showcased durable antitumor activity and tolerability in patients with malignant mesothelioma and other solid tumors harboring NF2 mutations, according to data from a phase 1 trial presented at the 2023 AACR Annual Meeting.

ASTRO/ESTRO Release Clinical Guideline for Local Therapy in Oligometastatic NSCLC

April 26th 2023

The American Society for Radiation Oncology and European Society for Radiotherapy & Oncology have released the first clinical guideline on the use of definitive local therapy, including radiation and surgery, for the treatment of patients with oligometastatic non–small cell lung cancer.

Furmonertinib Plus Icotinib Elicits Antitumor Activity in EGFR+ NSCLC With CNS Metastases

April 26th 2023

First-line treatment with furmonertinib plus icotinib induced responses in patients with EGFR-mutant non–small cell lung cancer. including those with central nervous system metastases, according to data from an ongoing phase 2 trial.

Subgrouping Patients with Advanced NSCLC for Tailored Treatment

April 25th 2023

The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.

Overview of PD-L1 Testing in Advanced NSCLC

April 25th 2023

Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.

AZD3759 Elicits Responses in Untreated EGFR-Mutant NSCLC With CNS Metastases

April 25th 2023

AZD3759 elicited clinical responses and had an acceptable toxicity profile when administered at a dose of 200 mg twice daily in patients with untreated EGFR-mutant non–small cell lung cancer and central nervous system metastases, according to data from the phase 2 TRUMP trial.

Durvalumab Plus Chemo Is Tolerable in Real-World Representative ES-SCLC Population

April 25th 2023

First-line durvalumab plus up to 6 cycles of platinum and etoposide is safe and tolerable with signals of clinical efficacy consistent with those previously seen in patients with treatment-naïve extensive-stage small cell lung cancer.

Dr Herbst on the Implications of the AEGEAN Trial in NSCLC

April 24th 2023

Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Subgroup Analysis Shows Consistent Benefit for Dostarlimab Plus Chemo in Nonsquamous NSCLC

April 24th 2023

Overall response rates were similar across subgroups of patients with nonsquamous non–small cell lung cancer for the combinations of dostarlimab-gxly plus chemotherapy and pembrolizumab plus chemotherapy, and responses numerically favored the dostarlimab-based combination in most subgroups, according to a subgroup analysis of the phase 2 PERLA trial.

Dr Reckamp on the Effect of Adjuvant Atezolizumab on Patient Outcomes in Resectable Stage IB-IIIA NSCLC

April 21st 2023

Karen L. Reckamp, MD, MS, discusses updated findings from the phase 2 LCMC3 trial in resectable stage IB to IIIB non–small cell lung cancer.

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors

April 20th 2023

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

IBI351 Demonstrates Early Antitumor Activity and Tolerability in KRAS G12C+ Advanced NSCLC

April 18th 2023

The recommended phase 2 dose of IBI351 monotherapy had favorable safety and encouraging efficacy signals when administered to patients with advanced KRAS G12C–mutated non–small cell lung cancer, according to updated data from a phase 1 dose-escalation study.

Novel KRAS G12C Inhibitor Shows Early Signs of Efficacy Across Solid Tumors, Pretreated NSCLC

April 17th 2023

LY3537982, an investigative KRAS G12C inhibitor, demonstrated clinical efficacy across patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

Perioperative Durvalumab Plus Neoadjuvant Chemo Improves pCR, EFS in Resectable NSCLC

April 16th 2023

Perioperative durvalumab plus neoadjuvant platinum-based chemotherapy demonstrated a statistically significant improvement in pathologic complete response and event-free survival vs placebo plus chemotherapy in patients with resectable non–small cell lung cancer.

Dr Liu on the Activity of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

April 14th 2023

Stephen V. Liu, MD, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer.

TIGIT Remains a Tempting Target for Immunotherapy Combinations, Despite Setbacks

April 13th 2023

Despite a high-profile clinical disappointment, the TIGIT immune checkpoint remains an important target for anticancer therapy, with research programs testing novel agents moving forward in non–small cell lung cancer and a range of other tumor types.

THIO Followed By Cemiplimab Displays Safety, Tolerability in Advanced NSCLC

April 11th 2023

The sequential combination of THIO plus cemiplimab did not lead to any dose-limiting toxicities or significant treatment-related adverse effects in patients with advanced non–small cell lung cancer.